Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Wednesday that it has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for IBI343 as monotherapy for advanced pancreatic cancer.
A potentially best-in-class TOPO1i anti-CLDN18.2 ADC, IBI343 was granted BTD for the treatment of CLDN18.2-positive advanced pancreatic ductal adenocarcinoma (PDAC) patients who have progressed after at least one line of prior systematic treatment.
An ongoing Phase 1 study in China, Australia and the United States has demonstrated favourable safety and tolerability and promising antitumour activity of IBI343 monotherapy in advanced PDAC patients. Data from the study's dose-expansion cohort were presented at the 2024 ESMO Asia Congress.
The study enrolled a total of 43 patients with CLDN18.2-positive advanced PDAC. Participants received IBI343 6 mg/kg Q3W monotherapy. All had previously received at least one line of prior therapy, and 60.5% had received two or more lines of anticancer treatment. During the study, the confirmed overall objective response rate (ORR) was 23.3% and progression-free survival (PFS) events occurred in 26 patients, with a median progression-free survival (mPFS) of 5.3 months (4.1-7.4) as of the data cutoff date.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma